Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics

Allemani, 2015, Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet Lond Engl, 385, 977, 10.1016/S0140-6736(14)62038-9 Fitzmaurice, 2015, The Global Burden of Cancer 2013, JAMA Oncol, 1, 505, 10.1001/jamaoncol.2015.0735 Pai, 2000, Cardiotoxicity of Chemotherapeutic Agents, Drug Saf, 22, 263, 10.2165/00002018-200022040-00002 Ray, 2012, Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling, Cell Signal, 24, 981, 10.1016/j.cellsig.2012.01.008 Belch, 1991, Oxygen free radicals and congestive heart failure, Br Heart J, 65, 245, 10.1136/hrt.65.5.245 Fariss, 2005, Role of mitochondria in toxic oxidative stress, Mol Interv, 5, 94, 10.1124/mi.5.2.7 Dröge, 2002, Free radicals in the physiological control of cell function, Physiol Rev, 82, 47, 10.1152/physrev.00018.2001 Turrens, 2003, Mitochondrial formation of reactive oxygen species, J Physiol, 552, 335, 10.1113/jphysiol.2003.049478 Angsutararux, 2015, Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress, Oxid Med Cell Longev, 2015, 10.1155/2015/795602 Becker, 1999, Generation of superoxide in cardiomyocytes during ischemia before reperfusion, Am J Physiol, 277, H2240 Bergamini, 2004, Oxygen, reactive oxygen species and tissue damage, Curr Pharm Des, 10, 1611, 10.2174/1381612043384664 Ambrosio, 1993, Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow, J Biol Chem, 268, 18532, 10.1016/S0021-9258(17)46660-9 Paradies, 2004, Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin, Circ Res, 94, 53, 10.1161/01.RES.0000109416.56608.64 Paradies, 2000, The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles, FEBS Lett, 466, 323, 10.1016/S0014-5793(00)01082-6 Medzhitov, 2010, Inflammation 2010: new adventures of an old flame, Cell, 140, 771, 10.1016/j.cell.2010.03.006 Lazzerini, 2015, Long QT Syndrome: An Emerging Role for Inflammation and Immunity, Front Cardiovasc Med, 2, 26, 10.3389/fcvm.2015.00026 Lazzerini, 2019, Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies, Nat Rev Immunol, 19, 63, 10.1038/s41577-018-0098-z Aromolaran, 2018, Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation, PLOS ONE, 13, 10.1371/journal.pone.0208321 Alí, 2018, Cardiolipotoxicity, Inflammation, and Arrhythmias: Role for Interleukin-6 Molecular Mechanisms, Front Physiol, 9, 1866, 10.3389/fphys.2018.01866 Hagiwara, 2007, SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes, J Mol Cell Cardiol, 43, 710, 10.1016/j.yjmcc.2007.09.004 Villegas, 2000, Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes, Basic Res Cardiol, 95, 47, 10.1007/s003950050007 Tanaka, 2004, Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes, J Int Med Res, 32, 57, 10.1177/147323000403200109 Fontes, 2015, The varying faces of IL-6: From cardiac protection to cardiac failure, Cytokine, 74, 62, 10.1016/j.cyto.2014.12.024 Yamauchi-Takihara, 2000, Cytokines and their receptors in cardiovascular diseases — role of gp130 signalling pathway in cardiac myocyte growth and maintenance, Int J Exp Pathol, 81, 1, 10.1046/j.1365-2613.2000.00139.x Feldman, 2000, The role of tumor necrosis factor in the pathophysiology of heart failure, J Am Coll Cardiol, 35, 537, 10.1016/S0735-1097(99)00600-2 Petkova-Kirova, 2006, Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha, Am J Physiol Heart Circ Physiol, 290, H2098, 10.1152/ajpheart.00097.2005 Shi, 2021, GSDMD-Mediated Cardiomyocyte Pyroptosis Promotes Myocardial I/R Injury, Circ Res, 129, 383, 10.1161/CIRCRESAHA.120.318629 Li, 2020, MicroRNA-129-1-3p protects cardiomyocytes from pirarubicin-induced apoptosis by down-regulating the GRIN2D-mediated Ca2+ signalling pathway, J Cell Mol Med, 24, 2260, 10.1111/jcmm.14908 Sag, 2011, CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes, J Mol Cell Cardiol, 51, 749, 10.1016/j.yjmcc.2011.07.016 Cappetta, 2017, Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction, Br J Pharmacol, 174, 3696, 10.1111/bph.13791 Sutanto, 2020, Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies, Prog Biophys Mol Biol, 157, 54, 10.1016/j.pbiomolbio.2020.02.008 Förstermann, 2006, Endothelial nitric oxide synthase in vascular disease, Circulation, 113, 1708, 10.1161/CIRCULATIONAHA.105.602532 Shashar, 2017, Vascular endothelial growth factor augments arginine transport and nitric oxide generation via a KDR receptor signaling pathway, Kidney Blood Press Res, 42, 201, 10.1159/000476016 Mamoshina, 2021, Toward a broader view of mechanisms of drug cardiotoxicity, Cell Rep Med, 2 Taimeh, 2013, Vascular endothelial growth factor in heart failure, Nat Rev Cardiol, 10, 519, 10.1038/nrcardio.2013.94 Izzedine, 2009, Management of hypertension in angiogenesis inhibitor-treated patients, Ann Oncol Off J Eur Soc Med Oncol, 20, 807, 10.1093/annonc/mdn713 Kappers, 2010, Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels, Hypertens Dallas Tex 1979, 56, 675 Oka, 2014, Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure, Circ Res, 114, 565, 10.1161/CIRCRESAHA.114.300507 Chintalgattu, 2010, Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress, J Clin Invest, 120, 472, 10.1172/JCI39434 Pondé, 2016, Twenty years of anti-HER2 therapy-associated cardiotoxicity, ESMO Open, 1, 10.1136/esmoopen-2016-000073 Goodwill, 2017, Regulation of Coronary Blood Flow, Compr Physiol, 7, 321, 10.1002/cphy.c160016 Ogobuiro I, Wehrle CJ, Tuma F. Anatomy, thorax, heart coronary arteries. in: statpearls. statpearls publishing; 2022. Available at: http://www.ncbi.nlm.nih.gov/books/NBK534790/, Accessed August 21, 2022. Solaro, 2011 Saleh, 2018, Understanding myocardial infarction, F1000Research, 7, 10.12688/f1000research.15096.1 Shahjehan, 2022, Coronary Artery Disease Herrmann, 2016, Vascular toxicities of cancer therapies: The old and the new - An evolving avenue, Circulation, 133, 1272, 10.1161/CIRCULATIONAHA.115.018347 Venkatesh, 2022, Anthracyclines Martins-Teixeira, 2020, Antitumour anthracyclines: progress and perspectives, ChemMedChem, 15, 933, 10.1002/cmdc.202000131 Volkova, 2022, Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr Cardiol Rev, 7, 214, 10.2174/157340311799960645 Cardinale, 2020, Cardiotoxicity of Anthracyclines, Front Cardiovasc Med., 7, 26, 10.3389/fcvm.2020.00026 Ichikawa, 2014, Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation, J Clin Invest, 124, 617, 10.1172/JCI72931 Octavia, 2012, Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies, J Mol Cell Cardiol, 52, 1213, 10.1016/j.yjmcc.2012.03.006 Pecoraro, 2016, Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity, Toxicol Appl Pharmacol, 293, 44, 10.1016/j.taap.2016.01.006 Assomull, 2006, Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy, J Am Coll Cardiol, 48, 1977, 10.1016/j.jacc.2006.07.049 McGowan, 2017, Anthracycline Chemotherapy and Cardiotoxicity, Cardiovasc Drugs Ther, 31, 63, 10.1007/s10557-016-6711-0 Alexander, 1979, Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography, N Engl J Med, 300, 278, 10.1056/NEJM197902083000603 Swain, 2003, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer, 97, 2869, 10.1002/cncr.11407 Saleh, 2021, Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment, Heart Fail Rev, 26, 1159, 10.1007/s10741-020-09968-2 Role of NADPH Oxidase-Mediated Reactive Oxygen Species in Podocyte Injury. Available at: https://www.hindawi.com/journals/bmri/2013/839761/, Accessed August 21, 2022. Lubieniecka, 2013, A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor, Front Genet, 4, 231, 10.3389/fgene.2013.00231 Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques | Heart. Available at: https://heart.bmj.com/content/88/1/81, Accessed August 21, 2022. 2022, Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia, J Clin Oncol Orphanos, 2009, Cardiotoxicity induced by tyrosine kinase inhibitors, Acta Oncol Stockh Swed, 48, 964, 10.1080/02841860903229124 Sestier, 2021, Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation, Curr Oncol Rep, 23, 113, 10.1007/s11912-021-01102-1 Lee, 2018, Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy, Mol Cell Toxicol, 14, 247, 10.1007/s13273-018-0027-z Chen, 2008, Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics, Circulation, 118, 84, 10.1161/CIRCULATIONAHA.108.776831 Paul, 2004, Tyrosine kinase – role and significance in cancer, Int J Med Sci, 101, 10.7150/ijms.1.101 Lahiry, 2010, Kinase mutations in human disease: interpreting genotype-phenotype relationships, Nat Rev Genet, 11, 60, 10.1038/nrg2707 Krause, 2005, Tyrosine kinases as targets for cancer therapy, N Engl J Med, 353, 172, 10.1056/NEJMra044389 Nazer, 2011, Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: Focus on hypertension, Circulation, 124, 1687, 10.1161/CIRCULATIONAHA.110.992230 Veronese, 2006, Mechanisms of hypertension associated with BAY 43-9006, J Clin Oncol Off J Am Soc Clin Oncol, 24, 1363, 10.1200/JCO.2005.02.0503 Ayach, 2006, Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction, Proc Natl Acad Sci U S A., 103, 2304, 10.1073/pnas.0510997103 Fazel, 2006, Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines, J Clin Invest, 116, 1865, 10.1172/JCI27019 Chu, 2007, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet Lond Engl, 370, 2011, 10.1016/S0140-6736(07)61865-0 Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002;105(5):608–13. Xu, 2009, Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy, Hematol Rep., 1, e4, 10.4081/hr.2009.e4 Cheng, 2021, Tyrosine kinase inhibitors-induced arrhythmias: from molecular mechanisms, pharmacokinetics to therapeutic strategies, Front Cardiovasc Med, 8, 10.3389/fcvm.2021.758010 Jiang, 2019, Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium, Heart Rhythm, 16, 1374, 10.1016/j.hrthm.2019.04.008 Schramm, 2015, Targeted therapies in HER2-positive breast cancer - a systematic review, Breast Care, 10, 173, 10.1159/000431029 Barok, 2014, Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Res BCR, 16, 209, 10.1186/bcr3621 Gajria, 2011, HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies, Expert Rev Anticancer Ther, 11, 263, 10.1586/era.10.226 Yakes, 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action, Cancer Res, 62, 4132 Yang, 2021, Cardiotoxicity of epidermal growth factor receptor 2-targeted drugs for breast cancer, Front Pharmacol, 12 Mohan, 2018, Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers, Antib Ther, 1, 13 Bowles, 2012, Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study, J Natl Cancer Inst, 104, 1293, 10.1093/jnci/djs317 Vasti, 2014, Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines, World J Cardiol, 6, 653, 10.4330/wjc.v6.i7.653 Martel, 2017, Breast cancer treatment-induced cardiotoxicity, Expert Opin Drug Saf, 16, 1021, 10.1080/14740338.2017.1351541 Nunes, 2017, Proteasome inhibitors: structure and function, Semin Oncol, 44, 377, 10.1053/j.seminoncol.2018.01.004 Wu, 2020, Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management, Curr Oncol Rep, 22, 66, 10.1007/s11912-020-00931-w Hideshima, 2011, Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma, Mol Cancer Ther, 10, 2034, 10.1158/1535-7163.MCT-11-0433 Hideshima, 2001, The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications, Oncogene, 20, 4519, 10.1038/sj.onc.1204623 Perel, 2016, Carfilzomib (Kyprolis): a novel proteasome inhibitor for relapsed and/or refractory multiple myeloma, Pharm Ther, 41, 303 Cole, 2018, Cardiovascular complications of proteasome inhibitors used in multiple myeloma, Cardiol Rev, 26, 122, 10.1097/CRD.0000000000000183 Lee, 2018, Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention, Curr Treat Options Cardiovasc Med, 20, 19, 10.1007/s11936-018-0618-y Dimopoulos, 2016, Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study, Lancet Oncol, 17, 27, 10.1016/S1470-2045(15)00464-7 Meseeha, 2015, Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy, J Community Hosp Intern Med Perspect, 5, 28982, 10.3402/jchimp.v5.28982 Ogino, 2022, Cyclophosphamide Ahlmann, 2016, The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy, Cancer Chemother Pharmacol, 78, 661, 10.1007/s00280-016-3152-1 Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy | JAMA Internal Medicine | JAMA Network. Available at: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/601073, Accessed August 22, 2022. Dhesi, 2013, Cyclophosphamide-induced cardiomyopathy, J Investig Med High Impact Case Rep, 1 Iqubal, 2019, Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision, Life Sci, 218, 112, 10.1016/j.lfs.2018.12.018 Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention | PLOS ONE. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0131394, Accessed August 22, 2022. Rowinsky, 1991, Cardiac disturbances during the administration of taxol, J Clin Oncol, 9, 1704, 10.1200/JCO.1991.9.9.1704 McGuire, 1989, Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann Intern Med, 111, 273, 10.7326/0003-4819-111-4-273 Joshi, 2021, Microtubule inhibitors and cardiotoxicity, Curr Oncol Rep, 23, 30, 10.1007/s11912-021-01014-0 Osman, 2017, A prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction, Breast Care Basel Switz, 12, 255, 10.1159/000471759 Yeh, 2009, Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management, J Am Coll Cardiol, 53, 2231, 10.1016/j.jacc.2009.02.050 Salvatorelli, 2006, Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies, J Pharmacol Exp Ther, 318, 424, 10.1124/jpet.106.103846 Colombo, 1999, Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin, Ann Oncol, 10, 391, 10.1023/A:1008309916974 Mortimer, 1992, A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors: A southwest oncology group study, Cancer, 69, 1220, 10.1002/cncr.2820690525 Tomirotti, 1984, Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP), Tumori, 70, 235, 10.1177/030089168407000305 Jakubowski, 1988, Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil, Cancer, 62, 266, 10.1002/1097-0142(19880715)62:2<266::AID-CNCR2820620207>3.0.CO;2-Y Patanè, 2014, Cardiotoxicity: Cisplatin and long-term cancer survivors, Int J Cardiol, 175, 201, 10.1016/j.ijcard.2014.04.238 El-Awady, 2011, Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies, Eur J Pharmacol, 650, 335, 10.1016/j.ejphar.2010.09.085 Dasari, 2014, Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol, 740, 364, 10.1016/j.ejphar.2014.07.025 Saleh, 2015, Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats, Eur J Pharmacol, 765, 574, 10.1016/j.ejphar.2015.09.015 Chirino, 2009, Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity, Exp Toxicol Pathol, 61, 223, 10.1016/j.etp.2008.09.003 Seng, 2012, Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and meta-analysis, J Clin Oncol, 30, 4416, 10.1200/JCO.2012.42.4358 Lechner, 2007, Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity, J Thromb Haemost, 5, 2445, 10.1111/j.1538-7836.2007.02788.x Monreal, 2006, Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry, Am J Med, 119, 1073, 10.1016/j.amjmed.2006.04.028 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Lamberti, 2014, A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives, Toxicol Lett, 227, 151, 10.1016/j.toxlet.2014.03.018 Brell, 2021, 5-fluorouracil cardiotoxicity: known but unknown, JACC CardioOncology, 3, 110, 10.1016/j.jaccao.2021.01.006 Zafar, 2021, The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm, JACC CardioOncology, 3, 101, 10.1016/j.jaccao.2020.12.005 Ang, 2010, Capecitabine-induced cardiotoxicity: case report and review of the literature, Curr Oncol, 17, 59, 10.3747/co.v17i1.437 Abdelmaseih, 2021, Cardio-oncology: Capecitabine can sometimes be heatbreaking capecitabine-induced takotsubo cardiomyopathy case report and literature review, Curr Probl Cardiol, 46, 10.1016/j.cpcardiol.2021.100854 Kanduri, 2019, Fluoropyrimidine-Associated Cardiotoxicity, Cardiol Clin, 37, 399, 10.1016/j.ccl.2019.07.004 Alter, 2006, Cardiotoxicity of 5-fluorouracil, Cardiovasc Hematol Agents Med Chem, 4, 1, 10.2174/187152506775268785 Cwikiel, 1996, The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits, Scanning Microsc, 10, 805 Senkus, 2011, Cardiovascular effects of systemic cancer treatment, Cancer Treat Rev, 37, 300, 10.1016/j.ctrv.2010.11.001 Thyss, 1992, Very high endothelin plasma levels in patients with 5-FU cardiotoxicity, Ann Oncol Off J Eur Soc Med Oncol, 3, 88 Akhtar, 1993, Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study, Oncology, 50, 441, 10.1159/000227226 Zamorano, 2016, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines, Kardiol Pol, 74, 1193, 10.5603/KP.2016.0156 Anderson, 2005, Lenalidomide and thalidomide: mechanisms of action–similarities and differences, Semin Hematol, 42, S3, 10.1053/j.seminhematol.2005.10.001 Fahdi, 2004, Bradycardia during therapy for multiple myeloma with thalidomide, Am J Cardiol, 93, 1052, 10.1016/j.amjcard.2003.12.061 Meyer, 2008, Thalidomide causes sinus bradycardia in ALS, J Neurol, 255, 587, 10.1007/s00415-008-0756-3 Moudgil, 2016, Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: Cardiomyopathy and beyond, Can J Cardiol, 32, 863, 10.1016/j.cjca.2016.01.027 Emch, 2002, Tumor necrosis factor-alpha inhibits physiologically identified dorsal motor nucleus neurons in vivo, Brain Res, 951, 311, 10.1016/S0006-8993(02)03178-5 Carver, 2010, Myocarditis during lenalidomide therapy, Ann Pharmacother, 44, 1840, 10.1345/aph.1P044 Kaur, 2003, Thalidomide-induced sinus bradycardia, Ann Pharmacother, 37, 1040, 10.1345/aph.1D003 Minnema, 2003, Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment, J Thromb Haemost JTH, 1, 445, 10.1046/j.1538-7836.2003.00083.x Kaushal, 2002, Endothelial dysfunction in antiangiogenesis-associated thrombosis, J Clin Oncol Off J Am Soc Clin Oncol., 20, 3042, 10.1200/JCO.2002.20.13.3042 Carrier, 2011, Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis, J Thromb Haemost JTH, 9, 653, 10.1111/j.1538-7836.2011.04215.x Desai, 2002, A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma, Cancer, 95, 1629, 10.1002/cncr.10847 Arboscello, 2010, Thalidomide-induced cardiotoxicity in multiple myeloma patients: An underestimated but clinically relevant issue, J Clin Oncol, 28, e18544, 10.1200/jco.2010.28.15_suppl.e18544 Bodai, 2015, Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations, Perm J, 19, 48, 10.7812/TPP/14-241 Hershman, 2008, Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-hodgkin's lymphoma, J Clin Oncol, 26, 3159, 10.1200/JCO.2007.14.1242 Hequet, 2004, Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults, J Clin Oncol, 22, 1864, 10.1200/JCO.2004.06.033 McMaster, 1991, A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma, Cancer, 67, 1487, 10.1002/1097-0142(19910315)67:6<1487::AID-CNCR2820670604>3.0.CO;2-S Hainsworth, 2003, First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-hodgkin's lymphoma: phase ii trial, Clin Lymphoma, 4, 36, 10.3816/CLM.2003.n.012 Altena, 2021, Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer, Cardio-Oncol, 7, 20, 10.1186/s40959-021-00105-y Tan, 2012, Assessing the cardiac toxicity of chemotherapeutic agents: role of echocardiography, Curr Cardiovasc Imaging Rep, 5, 403, 10.1007/s12410-012-9163-3 Mulvagh, 2008, American society of echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography, J Am Soc Echocardiogr, 21, 1179, 10.1016/j.echo.2008.09.009 Pepe, 2016, Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology, J Cardiovasc Med Hagerstown Md., 17, e45, 10.2459/JCM.0000000000000380 Perazzolo Marra, 2014, Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy, Heart Rhythm, 11, 856, 10.1016/j.hrthm.2014.01.014 Zardavas, 2017, J Clin Oncol, 35, 878, 10.1200/JCO.2015.65.7916 Cardinale, 2000, Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy, J Am Coll Cardiol, 36, 517, 10.1016/S0735-1097(00)00748-8 Ky, 2014, Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab, J Am Coll Cardiol, 63, 809, 10.1016/j.jacc.2013.10.061 Pistillucci, 2015, Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab, Clin Ter, 166, e67 Wang, 2016, Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity, Oncol Lett, 11, 3483, 10.3892/ol.2016.4424 Sawaya, 2011, Early detection and prediction of cardiotoxicity in chemotherapy-treated patients, Am J Cardiol, 107, 1375, 10.1016/j.amjcard.2011.01.006 Sawaya, 2012, Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab, Circ Cardiovasc Imaging, 5, 596, 10.1161/CIRCIMAGING.112.973321 Mosca, 2011, Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the american heart association, Circulation, 123, 1243, 10.1161/CIR.0b013e31820faaf8 Adıyaman, 2021, Effects of grapeseed extract on doxorubicin-induced cardiotoxicity in rats, Herz, 46, 103, 10.1007/s00059-019-04888-w Razmaraii, 2016, Cardioprotective effect of grape seed extract on chronic doxorubicin-induced cardiac toxicity in wistar rats, Adv Pharm Bull, 6, 423, 10.15171/apb.2016.055 A Scientific Validation of Antihyperglycemic and Antihyperlipidemic Attributes of Trichosanthes dioica. Available at: https://www.hindawi.com/journals/isrn/2013/473059/, Accessed August 23, 2022. Alam, 2011, Antioxidant, anti-inflannnatory and anti-pyretic activities of trichosanthes dioica roxb, Fruits Bhattacharya, 2012, Protective role of the triterpenoid-enriched extract of Trichosanthes dioica root against experimentally induced pain and inflammation in rodents, Nat Prod Res, 26, 2348, 10.1080/14786419.2012.656111 Khandaker, 2018, Trichosanthes dioica Roxb.: A vegetable with diverse pharmacological properties, Food Sci Hum Wellness, 7, 34, 10.1016/j.fshw.2017.12.005 Palomo, 2017, Associations Between Exercise Prior to And Around The Time of Cancer Diagnosis And Subsequent Cardiovascular Events in Women With Breast Cancer: A Women's Health Initiative (WHI) Analysis, J Am Coll Cardiol, 11, 1774, 10.1016/S0735-1097(17)35163-X Segal, 2009, Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol, 27, 344, 10.1200/JCO.2007.15.4963 Wang, 2018, Aerobic exercise during early murine doxorubicin exposure mitigates cardiac toxicity, J Pediatr Hematol Oncol, 40, 208, 10.1097/MPH.0000000000001112 Wang, 2021, Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity, Cancer Med, 10, 7572, 10.1002/cam4.4283 Langer, 2014, Dexrazoxane for the treatment of chemotherapy-related side effects, Cancer Manag Res, 6, 357, 10.2147/CMAR.S47238 Hasinoff, 2007, Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?, Cardiovasc Toxicol, 7, 140, 10.1007/s12012-007-0023-3 Lyu, 2007, Topoisomerase IIbeta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane, Cancer Res, 67, 8839, 10.1158/0008-5472.CAN-07-1649 Macedo, 2019, Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer, JACC CardioOncology, 1, 68, 10.1016/j.jaccao.2019.08.003 Kalay, 2006, Protective effects of carvedilol against anthracycline-induced cardiomyopathy, J Am Coll Cardiol, 48, 2258, 10.1016/j.jacc.2006.07.052 Cirmi, 2020, Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: An analysis of the FDA Adverse Event Reporting System Database (FAERS), Cancers, 12, E826, 10.3390/cancers12040826 Chaar, 2018, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities, OncoTargets Ther, 11, 6227, 10.2147/OTT.S170138 Heidenreich, 2022, 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: A report of the american college of cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation, 145, e876 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Chari, 2014, Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring, BMC Cancer, 14, 915, 10.1186/1471-2407-14-915 Mikhael, 2016, Management of carfilzomib-associated cardiac adverse events, Clin Lymphoma Myeloma Leuk, 16, 241, 10.1016/j.clml.2016.01.008 Imam, 2017, Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-κB, hypertrophic gene expression and oxidative stress, Cardiovasc Toxicol, 17, 58, 10.1007/s12012-015-9356-5 Imam, 2016, Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats, Toxicol Mech Methods, 26, 700, 10.1080/15376516.2016.1236425 Al-Harbi, 2016, Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats, Toxicol Mech Methods, 26, 189, 10.3109/15376516.2016.1143071 Eneh C, Lekkala MR. Dexrazoxane. StatPearls. Treasure Island (FL)2022. Gulati, 2021, 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation, 144, e368 El Kiki, 2020, Metformin and/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1/SOD and BAX/Bcl-2 pathways in rats, Mol Biol Rep, 47, 5115, 10.1007/s11033-020-05582-5 Abd-ElRaouf, 2021, Low dose gamma irradiation attenuates cyclophosphamide-induced cardiotoxicity in rats: role of NF-κB signaling pathway, Int J Radiat Biol, 97, 632, 10.1080/09553002.2021.1893856 El-Agamy, 2017, Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate, Cancer Chemother Pharmacol, 79, 399, 10.1007/s00280-016-3233-1 Weiss, 1990, Hypersensitivity reactions from taxol, J Clin Oncol Off J Am Soc Clin Oncol, 8, 1263, 10.1200/JCO.1990.8.7.1263 Picard, 2015, Re-visiting hypersensitivity reactions to Taxanes: A comprehensive review, Clin Rev Allergy Immunol, 49, 177, 10.1007/s12016-014-8416-0 Perotti, 2003, Cardiotoxic effects of anthracycline - Taxane combinations, Expert Opin Drug Saf, 2, 59, 10.1517/14740338.2.1.59 Madeddu, 2016, Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy, J Cardiovasc Med Hagerstown Md, 17, S12, 10.2459/JCM.0000000000000376 Hu, 2018, Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature, Medicine (Baltimore), 97, e13807, 10.1097/MD.0000000000013807 Jiang, 2019, Thrombotic Risk from Chemotherapy and Other Cancer Therapies, Cancer Treat Res, 179, 87, 10.1007/978-3-030-20315-3_6 Layoun, 2016, Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management, Curr Oncol Rep, 18, 35, 10.1007/s11912-016-0521-1 Saif, 2009, Fluoropyrimidine-associated cardiotoxicity: revisited, Expert Opin Drug Saf, 8, 191, 10.1517/14740330902733961 Teperikidis, 2022, 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations, Acta Cardiol, 77, 1, 10.1080/00015385.2021.1873548 Le Brun-Ly, 2009, Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity, Oncology, 76, 322, 10.1159/000209336 Lestuzzi, 2010, Capecitabine cardiac toxicity presenting as effort angina: a case report, J Cardiovasc Med Hagerstown Md, 11, 700, 10.2459/JCM.0b013e328332e873 Ma, 2017, Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity, Cancer, 123, 345, 10.1002/cncr.30321 Raber, 2020, Uridine triacetate for severe fluoropyrimidine cardiotoxicity in a patient with thymidylate synthase gene variants, JACC CardioOncology, 2, 329, 10.1016/j.jaccao.2020.04.005 Garcia, 2018, Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency, Toxicol Appl Pharmacol, 353, 67, 10.1016/j.taap.2018.06.012 Palumbo, 2011, Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial, J Clin Oncol Off J Am Soc Clin Oncol, 29, 986, 10.1200/JCO.2010.31.6844 Kahale, 2021, Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents, Cochrane Database Syst Rev, 9 Palumbo, 2014, International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol, 32, 587, 10.1200/JCO.2013.48.7934 Cornell, 2020, Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents, Br J Haematol, 190, 555, 10.1111/bjh.16653 Dammacco, 2013, Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine, Clin Exp Med, 13, 85, 10.1007/s10238-013-0230-0 Stevens, 2021, Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report, Chest, 160, e545, 10.1016/j.chest.2021.07.055 Overview | Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | Guidance | NICE. Available at: https://www.nice.org.uk/guidance/ng158?UID=1062173854202112723151, Accessed August 24, 2022. Ewer, 2015, Cardiotoxicity of anticancer treatments, Nat Rev Cardiol, 12, 547, 10.1038/nrcardio.2015.65 Ewer, 2008, Cardiotoxicity profile of trastuzumab, Drug Saf, 31, 459, 10.2165/00002018-200831060-00002 Sara, 2018, 5-fluorouracil and cardiotoxicity: A review, Ther Adv Med Oncol, 10, 10.1177/1758835918780140 Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984 Maruyama, 2011, Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism, J Biol Chem, 286, 32790, 10.1074/jbc.M111.245985 Galiniak, 2019, Health benefits of resveratrol administration, Acta Biochim Pol, 66, 13 Bradamante, 2004, Cardiovascular protective effects of resveratrol, Cardiovasc Drug Rev, 22, 169, 10.1111/j.1527-3466.2004.tb00139.x Danz, 2009, Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway, Free Radic Biol Med, 46, 1589, 10.1016/j.freeradbiomed.2009.03.011 Bolli, 2020, Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: The CCTRN SENECA Trial, JACC CardioOncology, 2, 581, 10.1016/j.jaccao.2020.09.001